Allen B. King

1.8k total citations
51 papers, 1.3k citations indexed

About

Allen B. King is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Allen B. King has authored 51 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Endocrinology, Diabetes and Metabolism, 22 papers in Surgery and 9 papers in Molecular Biology. Recurrent topics in Allen B. King's work include Diabetes Management and Research (34 papers), Diabetes Treatment and Management (27 papers) and Pancreatic function and diabetes (20 papers). Allen B. King is often cited by papers focused on Diabetes Management and Research (34 papers), Diabetes Treatment and Management (27 papers) and Pancreatic function and diabetes (20 papers). Allen B. King collaborates with scholars based in United States, Denmark and United Kingdom. Allen B. King's co-authors include Séamus Sreenan, Stefano Del Prato, Manuel Muñoz‐Torres, Mustafa Kemal Balcı, Julio Rosenstock, Priscilla Hollander, Lars Endahl, Jiten Vora, P.‐M. Schumm‐Draeger and Ann Marie Ocampo Francisco and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Allen B. King

50 papers receiving 1.3k citations

Peers

Countries citing papers authored by Allen B. King

Since Specialization

Citations

This map shows the geographic impact of Allen B. King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allen B. King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allen B. King more than expected).

Fields of papers citing papers by Allen B. King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allen B. King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allen B. King. The network helps show where Allen B. King may publish in the future.

Co-authorship network of co-authors of Allen B. King

This figure shows the co-authorship network connecting the top 25 collaborators of Allen B. King. A scholar is included among the top collaborators of Allen B. King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allen B. King. Allen B. King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes 2016 ·Current Diabetes Reports ·Allen B. King, Akio Kuroda, Munehide Matsuhisa, Todd Hobbs	26
2	Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day? 2015 ·Expert Review of Clinical Pharmacology ·Richard J. Simpson, Allen B. King	3
3	Reassessment of Insulin Dosing Guidelines in Continuous Subcutaneous Insulin Infusion Treated Type 1 Diabetes 2014 ·Current Diabetes Reports ·Allen B. King	8
4	Individualizing Insulin Therapy in the Management of Type 2 Diabetes 2014 ·The American Journal of Medicine ·Etie S. Moghissi, Allen B. King	15
5	Omitting Late-Night Eating May Cause Hypoglycemia in “Well Controlled” Basal Insulin-Treated Type 2 Diabetes 2014 ·Endocrine Practice ·Allen B. King, (unknown)	7
6	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial 2012 ·The Lancet ·Alan J. Garber, Allen B. King, Stefano Del Prato, Séamus Sreenan, Mustafa Kemal Balcı, Manuel Muñoz‐Torres, Julio Rosenstock, Lars Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander	265
7	Liraglutide Achieves A1C Targets More often than Sitagliptin or Exenatide when Added to Metformin in Patients with Type 2 Diabetes and a Baseline A1C <8.0% 2012 ·Endocrine Practice ·Allen B. King, Eduard Montanya, Richard E. Pratley, Lawrence Blonde, Claus Bo Svendsen, Morten Donsmark, Giorgio Sesti	19
8	How Much do I Give? Dose Estimation Formulas for Once-Nightly Insulin Glargine and Premeal Insulin Lispro in type 1 Diabetes Mellitus 2012 ·Endocrine Practice ·Allen B. King, (unknown), (unknown)	8
9	Contribution of the Dawn Phenomenon to the Fasting and Postbreakfast Hyperglycemia In Type 1 Diabetes Treated With Once-Nightly Insulin Glargine 2012 ·Endocrine Practice ·Allen B. King, (unknown), (unknown)	15
10	A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations 2011 ·Diabetes Obesity and Metabolism ·Marc Evans, P.‐M. Schumm‐Draeger, Jiten Vora, Allen B. King	109
11	Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs 2010 ·Drug Healthcare and Patient Safety ·Allen B. King, (unknown)	42
12	How Much Do I Give? Reevaluation of Insulin Dosing Estimation Formulas Using Continuous Glucose Monitoring 2010 ·Endocrine Practice ·Allen B. King	21
13	Comparison of the Post-Meal Glucose Response to Different Insulin Bolus Waveforms in Insulin Pump- and Pre-Meal Pramlintide-Treated Type 1 Diabetes Patients 2010 ·Diabetes Technology & Therapeutics ·Allen B. King	6
14	Evaluation of a diabetes specialist–guided primary care diabetes treatment program 2009 ·Journal of the American Academy of Nurse Practitioners ·Allen B. King, (unknown)	13
15	Once‐daily insulin detemir is comparable to once‐daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double‐blind, randomized, crossover study 2008 ·Diabetes Obesity and Metabolism ·Allen B. King	33
16	Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal‐only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14‐week follow‐up data from PREDICTIVE™ 2007 ·Diabetes Obesity and Metabolism ·Anne Dornhorst, (unknown), Christoph Koenen, Markus Meriläinen, Allen B. King, (unknown), Séamus Sreenan, (unknown)	46
17	Exploring Methods to Extend the Reach of Diabetes Specialist Expertise Into Primary Care Clinics 2006 ·The Diabetes Educator ·Allen B. King, (unknown), (unknown), (unknown), Steve Harrison, (unknown), (unknown)	5
18	Basal Bolus Dosing: A Clinical Experience 2005 ·Current Diabetes Reviews ·Allen B. King, (unknown)	18
19	Effects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records 2002 ·Clinical Therapeutics ·Patrick J. Boyle, Allen B. King, Leann Olansky, Albert Marchetti, Helen Lau, Raf Magar, John P. Martin	140
20	EFFECT OF EXOGENOUS DOPAMINE ON RAT ADRENAL ASCORBIC ACID 1968 ·Journal of Pharmacology and Experimental Therapeutics ·Allen B. King, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact